What analysts say about IOVA stock - Dynamic capital growth
Autocar Professionalarrow_outwardWhat drives IOVA stock price - Outperformance with explosive growth
Jammu Links Newsarrow_outwardWhat analysts say about IOVA stock - Free Consultation
PrintWeek Indiaarrow_outwardNew Analyst Forecast: $IOVA Given $25.0 Price Target - Quiver Quantitative
Quiver Quantitativearrow_outwardWhat drives IOVA stock price - Outperformance with explosive growth - jammulinksnews.com
Jammulinksnews.comarrow_outwardIovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Seeking Alphaarrow_outwardWhat analysts say about IOVA stock - Free Consultation - printweek.in
Printweek.inarrow_outwardIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Simplywall.starrow_outwardWhy IOVA stock attracts strong analyst attention - Elite Investor Club - beatles.ru
Beatles.ruarrow_outwardIovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Defense Worldarrow_outward$IOVA stock is up 9% today. Here's what we see in our data. - Nasdaq
Nasdaqarrow_outwardWhy IOVA stock attracts strong analyst attention - Free Stock Market Knowledge Sharing - Newser
Newserarrow_outwardIovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - The Globe and Mail
The Globe and Mailarrow_outwardGoldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com
Investing.comarrow_outwardNew Real-World Data: Iovance's Melanoma Drug Amtagvi Achieves Breakthrough 61% Response Rate - Stock Titan
Stock Titanarrow_outwardIovance Biotherapeutics (IOVA): Navigating Legal Headwinds in a High-Risk, High-Reward Biotech Landscape - AInvest
AInvestarrow_outward3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MSN
MSNarrow_outward3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - FinancialContent
FinancialContentarrow_outwardGoldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance
Yahoo Financearrow_outward3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MarketBeat
MarketBeatarrow_outwardWhy Iovance Biotherapeutics Stock Dove by Almost 15% This Week - The Motley Fool
The Motley Foolarrow_outwardIovance Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA - Morningstar
Morningstararrow_outward(IOVA) On The My Stocks Page - news.stocktradersdaily.com
News.stocktradersdaily.comarrow_outwardIovance Biotherapeutics CCO Makes Bold Stock Purchase - TipRanks
TipRanksarrow_outwardShareholders Filed a Lawsuit Against $IOVA for Inflated Revenue Forecasts - TradingView
TradingViewarrow_outwardIOVA Stock News: Stockholders with Significant Losses Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - PR Newswire
PR Newswirearrow_outwardIOVA STOCK: Suffer Losses on Iovance Biotherapeutics, Inc.? - GlobeNewswire
GlobeNewswirearrow_outwardLawsuit filed for Investors who lost money with shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) - openPR.com
OpenPR.comarrow_outwardWhy Iovance Biotherapeutics (IOVA) Stock is Moving Today - GuruFocus
GuruFocusarrow_outwardWatkins Advises on Iovance Biotherapeutics’ US$211 Million Underwritten Offering of Common Stock - Latham & Watkins LLP
Latham & Watkins LLParrow_outward
Iova Stock close
- 2025-07-23 20:00 event
- 30 sourceslanguage
- 200+ ads_click
- 1 month ago schedule